PT - JOURNAL ARTICLE AU - Synolaki, Evgenia AU - Papadopoulos, Vasileios AU - Divolis, Georgios AU - Gavriilidis, Efstratios AU - Loli, Georgia AU - Gavriil, Arianna AU - Tsigalou, Christina AU - Tsahouridou, Olga AU - Sertaridou, Eleni AU - Rafailidis, Petros AU - Pasternack, Arja AU - Boumpas, Dimitrios AU - Germanidis, Georgios AU - Ritvos, Olli AU - Metallidis, Simeon AU - Skendros, Panagiotis AU - Sideras, Paschalis TI - Activin/Follistatin-axis deregulation is independently associated with COVID-19 in-hospital mortality AID - 10.1101/2020.09.05.20184655 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.05.20184655 4099 - http://medrxiv.org/content/early/2020/09/08/2020.09.05.20184655.short 4100 - http://medrxiv.org/content/early/2020/09/08/2020.09.05.20184655.full AB - Rationale Activins are inflammatory and tissue-repair-related members of the TGFβ-superfamily that have been implicated in the pathogenesis of several immuno-inflammatory disorders including sepsis/acute respiratory distress syndrome (ARDS). We hypothesized that they might be of particular relevance to COVID-19 pathophysiology.Objectives To assess the involvement of the Activin-Follistatin-axis in COVID-19 pathophysiology.Methods Levels of Activins -A, -B and their physiological inhibitor Follistatin, were retrospectively analyzed in 314 serum samples from 117 COVID-19 patients derived from two independent centers and compared with common demographic, clinical and laboratory parameters. Optimal-scaling with ridge-regression was used to screen variables and establish a prediction model.Main Results The Activin/Follistatin-axis was significantly deregulated during the course of COVID-19 and was independently associated with severity and in-hospital mortality. FACT-CLINYCoD, a novel disease scoring system, adding one point for each of Follistatin >6235 pg/ml, Activin-A >591 pg/ml, Activin-B >249 pg/ml, CRP >10.3 mg/dL, LDH >427 U/L, Intensive Care Unit (ICU) admission, Neutrophil/Lymphocyte-Ratio >5.6, Years of Age >61, Comorbidities >1 and D-dimers >1097 ng/ml, efficiently predicted and monitored fatal outcome independently of multiplicity and timing of sampling (AUC: 0.951±0.032, p<10-6). Validation in 35 samples derived from a third hospital indicated comparable AUC (0.958±0.086, p=0.032).Conclusion This study unravels the link between Activin/Folistatin-axis and COVID-19 mortality and introduces FACT-CLINYCoD, a novel pathophysiology-based tool that copes with the dynamic and heterogeneous nature of COCVID-19, predicts disease outcome and supports clinical decision making. Prospective large-scale validation of this calculator, as well as investigation of the mechanisms linking Activin/Folistatin-axis to COVID-19 pathogenesis is warranted.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN/AFunding StatementFunding: General Secretariat of Research and Technology, Greece, Grants: CYTONET (T1EDK-00617) and EATRIS-GR (OPS5028091).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Ethical Committees of all Institutes involved in the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are avaliable upon request.